Publication:
Consumption of Psychiatric Drugs in Primary Care during the COVID-19 Pandemic.

dc.contributor.authorGonzález-López, María Del Carmen
dc.contributor.authorDíaz-Calvo, Virginia
dc.contributor.authorRuíz-González, Carlos
dc.contributor.authorNievas-Soriano, Bruno José
dc.contributor.authorRebollo-Lavado, Belén
dc.contributor.authorParrón-Carreño, Tesifón
dc.date.accessioned2023-05-03T13:57:07Z
dc.date.available2023-05-03T13:57:07Z
dc.date.issued2022-04-14
dc.description.abstractThe main objective of this research was to analyze whether there were changes in the use of antidepressants, anxiolytics, and hypnotic-sedative drugs, in the context of primary health care, during the COVID-19 pandemic compared to the pre-pandemic period. We further sought to study consumption in vulnerable population groups. A cross-sectional observational study was performed in a primary health district of Spain. The data were obtained from the Andalusian Public Health System database, for the pre-COVID-19 period, from March 2019 to February 2020, and for the COVID-19 period, from March 2020 to February 2021. Univariant and bivariant analyses were performed. The effect size was measured using the Rosenthal test. While the total number of medical prescriptions decreased by 2.5% in the COVID-19 period, the prescriptions of psychiatric drugs increased by 6.1%. The increase in the dose consumption per 1000 inhabitants (DHD) was highest for anxiolytics (7.2%), followed by hypnotic-sedatives (5.6%) and antidepressants (3.7%). The consumption of antidepressants, anxiolytics, and sedative-hypnotic drugs was higher in women, older people, and rural areas and lower in areas with social transformation needs, with these differences being statistically significant. The consumption of psychiatric drugs has increased over the COVID-19 pandemic, especially in women, older people, and rural areas. Thus, we should reflect on the adequate use of these drugs.
dc.identifier.doi10.3390/ijerph19084782
dc.identifier.essn1660-4601
dc.identifier.pmcPMC9030027
dc.identifier.pmid35457647
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030027/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/1660-4601/19/8/4782/pdf?version=1649943307
dc.identifier.urihttp://hdl.handle.net/10668/21060
dc.issue.number8
dc.journal.titleInternational journal of environmental research and public health
dc.journal.titleabbreviationInt J Environ Res Public Health
dc.language.isoen
dc.organizationAlmería
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCOVID-19
dc.subjectantidepressants
dc.subjectanxiolytics
dc.subjectdrug consumption
dc.subjectdrug prescription
dc.subjecthypnotic-sedatives
dc.subjectprimary health care
dc.subjectpsychiatric drugs
dc.subject.meshAged
dc.subject.meshAnti-Anxiety Agents
dc.subject.meshAntidepressive Agents
dc.subject.meshCOVID-19
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypnotics and Sedatives
dc.subject.meshPandemics
dc.subject.meshPrimary Health Care
dc.subject.meshCOVID-19 Drug Treatment
dc.titleConsumption of Psychiatric Drugs in Primary Care during the COVID-19 Pandemic.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number19
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC9030027.pdf
Size:
723.93 KB
Format:
Adobe Portable Document Format